Arthanib 5 mg Tofacitinib
Tofacitinib is a potent and effective oral medication for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults. Arthanib 5 mg tablets contain Tofacitinib citrate, which works by inhibiting the signaling of cytokines, reducing inflammation, and easing the symptoms of these conditions. Tofacitinib blocks the activity of Janus kinases (JAKs) and prevents the phosphorylation and activation of signal transducers and activators of transcription (STATs). Arthanib can be taken orally as a 5 mg dose twice daily or as an extended-release 11 mg dose once daily, with or without food. It can be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Tofacitinib should not be used in people with known hypersensitivity to the drug or any other component of the product, or in those with severe liver impairment. It should be used with caution in people who may be at increased risk of gastrointestinal perforations and should not be used concurrently with live vaccines. Common side effects of Tofacitinib include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. The absorption of Tofacitinib may be increased when taken with potent inhibitors of cytochrome P450 (CYP) 3A4, such as ketoconazole, or with agents that affect both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19, such as fluconazole. Tofacitinib absorption may be reduced when taken with potent CYP3A4 inducers, such as rifampin. There is a risk of increased immunosuppression when Tofacitinib is taken with potent immunosuppressive drugs, such as azathioprine, tacrolimus, cyclosporine, and sirolimus. Pregnancy and lactation should be avoided while taking Tofacitinib. Arthanib 5 mg tablets should be stored at a temperature below 30°C in a dry place, protected from light and humidity, and kept out of reach of children.